1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,500 | 25,800 | 16:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Spyre Therapeutics announces pricing of $200 million public offering of common stock | 8 | Seeking Alpha | ||
| Di | Spyre Therapeutics Prices Public Offering Of About 7.28 Mln Shares At $27.50/shr | - | RTTNews | ||
| Mo | Spyre Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| Mo | Spyre Therapeutics launches $200 million public offering | 1 | Investing.com | ||
| Mo | Spyre Therapeutics, Inc. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| Mo | Spyre Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| Mo | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Spyre meldet vielversprechende Phase-1-Ergebnisse für IBD-Therapie | 3 | Investing.com Deutsch | ||
| 12.11. | Spyre reports promising Phase 1 results for IBD therapy | 1 | Investing.com | ||
| 12.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory ... | 83 | PR Newswire | SPY001 was well tolerated with a favorable safety profile consistent with the anti-a4ß7 class
SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase... ► Artikel lesen | |
| 08.11. | Spyre Therapeutics GAAP EPS of -$1.36 | 1 | Seeking Alpha | ||
| 07.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 23 | PR Newswire | Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation... ► Artikel lesen | |
| 07.11. | Spyre Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 07.11. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | Spyre Therapeutics-Direktor verkauft Aktien im Wert von 10.929 US-Dollar | - | Investing.com Deutsch | ||
| 25.10. | Guggenheim impressed by Spyre's 'diverse' portfolio, lifts shares target to $65 | 2 | Investing.com | ||
| 25.10. | Assenagon Asset Management S.A. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) | 1 | MarketBeat | ||
| 17.10. | Baird behält Outperform-Rating für Spyre-Aktie bei | 2 | Investing.com Deutsch | ||
| 17.10. | Baird retains Outperform rating on Spyre stock | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 10,000 | +0,96 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| MAINZ BIOMED | 0,200 | -4,99 % | Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| CENTOGENE | 0,070 | -1,41 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| GALAPAGOS NV | 23,960 | -0,33 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| CELLECTAR BIOSCIENCES | 1,380 | -6,76 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,470 | +1,29 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| AC IMMUNE | 3,015 | -1,47 % | AC Immune stock jumps 20% on data for Parkinson's disease drug | ||
| CHIMERIX | 0,847 | +1,07 % | Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,800 | -2,62 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| CYTOKINETICS | 48,000 | +1,27 % | Pharma-Offensive: Bayer schließt Millionen-Deal mit Cytokinetics - Rettung oder Risiko? | © Foto: picture alliance / Rupert Oberhäuser | Rupert OberhäuserBayer stärkt mit einem Millionen-Deal sein Herz-Kreislauf-Portfolio, doch Analysten bleiben skeptisch: Rechtsstreitigkeiten und Gewinne... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 20,800 | 0,00 % | Oruka Therapeutics, Inc. - 8-K, Current Report | ||
| SPERO THERAPEUTICS | 1,122 | -1,92 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| EIGER BIOPHARMACEUTICALS | 5,840 | 0,00 % | Eiger BioPharmaceuticals: Zock-Tipp liefert +864% in zweieinhalb Monaten | "In zwei Wochen winkt ein Börsenbeben", titelten wir zuletzt in weiser Voraussicht. Tatsächlich geht unser spekulativer Volltreffer Eiger BioPharmaceuticals (WKN: A3EKZU) allein gestern noch einmal... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +1,100 (+4,21 %) liegt der Kurs bei 27,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.
